Risk for Cancer Incidence, Mortality Increased With Psoriasis
Overall cancer incidence and mortality for kidney and other cancers up with severe psoriasis.
Kidney Cancer
KIDNEY CANCER
Longer Duration of Steroids May Affect Outcomes During Anti-PD-1 Treatment
The use of steroids for the treatment of immune-related adverse events may have survival consequences.
RCC With Isolated Lymph Node Metastases Has Poor Prognosis After Surgery
Following nephrectomy for renal cell carcinoma with lymph node involvement, patients have a 5-year survival rate of only 28%, a new study found.
Durable Positive Effects of First-Line Pembrolizumab in Advanced RCC Reported
Updated follow-up of patients in the KEYNOTE-427 trial showed that first-line pembrolizumab for advanced clear cell renal cell carcinoma exerts favorable antitumor activity after a median 23 months of follow-up.
Adjuvant Sorafenib Does Not Improve Survival in Renal Cell Carcinoma
Active surveillance remains the standard of care for patients at intermediate or high risk of recurrence following nephrectomy.
The Long-Term Health Effects of September 11, 2001
Renal & Urology News interviewed Michael Crane, MD, MPH, director of the WTC Health Program at Mount Sinai hospital about cancers and other long-term health problems linked with the events of September 11, 2001.
Cancer Survivors Face Long-Term Cardiovascular Risk
Risk varies by cardiovascular outcome and site of 20 common cancers
Unmarried Status Lessens Odds of mRCC Treatment
Unmarried vs married men have lower rates of receiving cytoreductive nephrectomy, metastasectomy, and systemic therapy use, and unmarried vs married women have lower rates of cytoreductive nephrecotomy and systemic therapy use, a study found.
CheckMate 214: Long-Term Results Confirm Superiority of Nivolumab Plus Ipilimumab for mRCC
Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.
Should Age Be a Barrier to Clinical Trial Participation for Older Patients With Metastatic Renal Cell Carcinoma?
A retrospective study compared older patients with mRCC with younger ones to determine if age and potential comorbidities is a barrier to clinical trial participation.
Want to read more?
Please login or register first to view this content.
Next post in Kidney Cancer
